

Mr Stephen Doyle PRDM, BPharm(Hons)

Chief Executive Officer, QBiotics Group, *BRISBANE*

Mr Stephen Doyle is Chief Executive Officer (CEO) of the QBiotics Group – an unlisted, public, Australian life sciences company specialising in the discovery and development of novel cell signalling small molecules.

Mr Doyle has almost 25 years' experience in the global medical and pharmaceutical sectors across a range of specialties in both developed and emerging markets.

Over the past two decades he has held numerous senior leadership roles in global pharmaceutical companies, including Sanofi Aventis and Boehringer Ingelheim.

A pharmacist by training, Mr Doyle commenced his pharmaceutical industry career at Janssen Cilag, and later moved to Novartis as a Senior Medical Affairs Associate.

Next, he was charged with overseeing the European and Asian scientific communication markets at Sanofi, followed by commercial operations in Sanofi's Oncology arm for each market over the ensuing decade.

At Boehringer Ingelheim, Mr Doyle led the Speciality Care Business Unit (Oncology, Biosimilars and Rare Diseases), and later the Diabetes Business Unit in Shanghai, overseeing new drug launches, partnerships and brand management.

Most recently, Mr Doyle served as Chief Business Officer (CBO) at ASLAN Pharmaceuticals, between 2018–2024, supporting the growth of their immunology and dermatology assets in late-stage development.

Mr Doyle holds a Master of Science in Clinical Pharmacy from the University of Derby, England, and a Bachelor of Science (Honours) in Pharmacy from Robert Gordon University, Aberdeen, Scotland.

"For 25 years, the QBiotics Group has seamlessly connected scientific discovery, development and commercialisation, leveraging our EcoLogic™ platform, to harness the power of nature, and identify small molecules with the greatest potential for pharmaceutical advancement.

"This platform has enabled us to utilise nature's abundant and remarkable chemical diversity, unmatched by synthetic chemistry, and to provide greater opportunity for the discovery of novel molecular structures and new modes of action," said Mr Doyle.

"A recent win for QBiotics and the Rare Cancers Australia community is reflected the promising outcomes from Stage 1 of our Phase IIa Soft Tissue Sarcoma trial, where the study met both its primary and secondary endpoints and tigilanol tiglate delivered patients an impressive 80% Objective Response Rate in injected tumours.

ends#



To coordinate an interview with Mr Stephen Doyle, please contact Kirsten Bruce, VIVA! Communications:

M +61 (0)401 717 566

T +61 (0)2 9968 3741 / 1604

E kirstenbruce@vivacommunications.com.au